Skip to content

A prospective, randomized, controlled, single blind clinical study of Shenqigui oral liquid for improving bone marrow suppression in patients with small cell lung cancer of Qi and yin deficiency type treated with chemotherapy

A prospective, randomized, controlled, single blind clinical study of Shenqigui oral liquid for improving bone marrow suppression in patients with small cell lung cancer of Qi and yin deficiency type treated with chemotherapy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044923
Enrollment
Unknown
Registered
2021-03-31
Start date
2021-04-03
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gas-yin two impeved small cell lung cancer

Interventions

Test group:Based on the treatment of the control group, 1d oral Shenqigui oral liquid, 10 mL, 2 times / d before the first chemotherapy cycle begins. The course of treatment is 22d.
Control group:None

Sponsors

Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Clinically, it is clearly diagnosed as a wide range of small cell lung cancer; 2.Chinese medicine is divided into gas and yin deficiency type; 3.Newly diagnosed with small cell lung cancer; 4.Compliance with the joint chemotherapy standard, parallel cycle treatment; 5.Age 18-75 years old, male or female; 6.Agree to receive traditional Chinese medicine treatment; 7.Informed consent and signed an informed consent book.

Exclusion criteria

Exclusion criteria: 1.Expected survival time < 3 months; 2.Merge hematopoietic dysfunction; 3.Women within pregnancy or lactation; 4.Severe mental illness; 5.Accompanied by severe heart and brain, liver, kidney and other diseases; 6.Unable to accept oral drug therapy; 7.Shenqigui oral liquid and its ingredient allergic; 8.Blood transfusion therapy; 9.Simultaneous radiotherapy.

Design outcomes

Secondary

MeasureTime frame
TCM syndrome score;Survival quality KPS rating;Classification of nausea and vomiting;Life quality score;

Primary

MeasureTime frame
Bone marrow suppression degree leveling and incidence;

Countries

China

Contacts

Public ContactYao Dejiao
531697523@qq.com+86 18981885782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026